Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its target price raised by investment analysts at Cantor Fitzgerald from $170.00 to $200.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has an "overweight" rating on the biotechnology company's stock. Cantor Fitzgerald's target price suggests a potential upside of 27.73% from the company's current price. Cantor Fitzgerald also issued estimates for Ascendis Pharma A/S's FY2025 earnings at ($2.72) EPS.

ASND has been the topic of several other research reports. UBS Group initiated coverage on shares of Ascendis Pharma A/S in a report on Tuesday, January 7th. They set a "buy" rating and a $196.00 price target on the stock. Stifel Nicolaus lifted their target price on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a "buy" rating in a research note on Friday, November 15th. TD Cowen cut their price target on Ascendis Pharma A/S from $160.00 to $153.00 and set a "buy" rating for the company in a research note on Friday, November 15th. Morgan Stanley set a $180.00 price target on Ascendis Pharma A/S in a report on Tuesday, February 18th. Finally, Evercore ISI upped their price objective on Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 18th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to data from MarketBeat, Ascendis Pharma A/S presently has a consensus rating of "Moderate Buy" and a consensus price target of $202.36.

Remove Ads

Ascendis Pharma A/S Trading Up 2.2 %

Ascendis Pharma A/S stock traded up $3.44 during trading on Tuesday, reaching $156.58. The company had a trading volume of 429,232 shares, compared to its average volume of 496,303. The firm's 50-day simple moving average is $136.11 and its 200 day simple moving average is $134.00. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $157.49. The firm has a market capitalization of $9.50 billion, a price-to-earnings ratio of -22.05 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($1.32) by $0.64. On average, analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Signaturefd LLC lifted its position in Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company's stock valued at $102,000 after purchasing an additional 80 shares during the last quarter. Virtus ETF Advisers LLC raised its position in shares of Ascendis Pharma A/S by 3.9% during the 4th quarter. Virtus ETF Advisers LLC now owns 2,676 shares of the biotechnology company's stock valued at $368,000 after buying an additional 100 shares in the last quarter. Legato Capital Management LLC lifted its holdings in shares of Ascendis Pharma A/S by 7.5% in the 4th quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company's stock valued at $264,000 after acquiring an additional 134 shares during the last quarter. Jones Financial Companies Lllp lifted its holdings in shares of Ascendis Pharma A/S by 394.0% in the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock valued at $34,000 after acquiring an additional 197 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in Ascendis Pharma A/S in the fourth quarter worth about $28,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.